Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2001-07-25
2008-09-09
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S135100, C424S143100, C424S144100, C424S153100, C424S155100, C424S156100, C424S173100, C424S174100, C424S800000, C424S801000, C530S387300, C530S388220, C530S388730, C530S388800, C530S388850, C530S389700, C530S808000, C530S867000
Reexamination Certificate
active
07422739
ABSTRACT:
Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.
REFERENCES:
patent: 4975278 (1990-12-01), Senter et al.
patent: 5439665 (1995-08-01), Hansen et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5648267 (1997-07-01), Reff
patent: 5677180 (1997-10-01), Robinson et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5843439 (1998-12-01), Anderson et al.
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6399061 (2002-06-01), Anderson et al.
patent: RE38008 (2003-02-01), Abrams et al.
patent: 6565827 (2003-05-01), Kaminski et al.
patent: 6652852 (2003-11-01), Robinson et al.
patent: 6682734 (2004-01-01), Anderson et al.
patent: 6893625 (2005-05-01), Robinson et al.
patent: 2002/0009444 (2002-01-01), Grillo-Lopez
patent: 2003/0021781 (2003-01-01), Anderson et al.
patent: 2003/0026804 (2003-02-01), Grillo-Lopez
patent: 2003/0082172 (2003-05-01), Anderson et al.
patent: 2003/0095963 (2003-05-01), Anderson et al.
patent: 2003/0206903 (2003-11-01), Grillo-Lopez
patent: 2004/0213784 (2004-10-01), Grilo-Lopez et al.
patent: 2005/0163708 (2005-07-01), Robinson et al.
patent: 2003/0147885 (2005-08-01), Anderson et al.
patent: 2005/0186205 (2005-08-01), Anderson et al.
patent: 0 125 023 (1984-11-01), None
patent: 0 125 023 (1984-11-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 274 394 (1988-07-01), None
patent: 0 274 394 (1988-07-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0 451 216 (1996-01-01), None
patent: 0 125 023 (2002-03-01), None
patent: WO 88/04936 (1988-07-01), None
patent: WO 91/04320 (1991-04-01), None
patent: WO 92/07466 (1992-05-01), None
patent: WO 93/02108 (1993-02-01), None
Idec Pharmaceuticals v. Corixa Corp., Case No. 01-1637-IEG [Doc. No. 486, 584] (S.D. Cal. Oct. 14, 2003).
Biogen Idec v. Corixa Corp., Case No. 01-1637-IEG [Doc. No. 635, 486] (S.D. Cal. Jan. 22, 2004).
Grossbard M.L., et al., “Monoclonal antibody-based therapies of leukemia and lymphoma,”Blood, 1992, 80:863-878.
Tedder T.F., et al., “Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes,”Eur J Immunol, 1986, 16(8):881-87.
Tedder T.F., et al., “Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19,”J Immunol, 1988, 141(12):4388-94.
Kaminski, et al., “Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody,”Antibody Immunoconjugates, and Radiopharmaceuticals, vol. 3, No. 1, Abstract No. 83.
Kaminski, et al., “Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody,”Proceedings of ASCO, vol. 9, p. 271, Abstract No. 1051.
Wahl, et al., “Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody,”The Journal of Nuclear Medicine: Proceedings of the 37thAnnual Meeting, p. 852, Abstract No. 622.
Kaminski, et al., “Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma,” 1990,Antibody Immunoconjugates, and Radiopharmaceuticals, vol. 4, No. 1, p. 36.
Kaminski, et al., “Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma,” 1990,Blood, vol. 76, No. 10, Abstract No. 1409.
Kaminski, et al., “Imaging, Dosimetry, and Radioimunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma,”Journal of Clinical Oncology, vol. 10, No. 11, pp. 1696-1711.
Adams, R.A. et al., Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2,Can Res 28:1121-1125 (1968).
Adams, Richard, Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma,Can. Res. 27:2479-2482 (1967).
Anderson, K.C., et al., Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow, Blood 69(2):597-604 (1987).
Anderson, D.R., et al., Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody, The Second Annual IBC International Conference on Antibody Engineering, Dec. 16-18, 1991.
Anderson, K.C., et al., Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation, Blood 63(6):1424-1433 (1984).
Appelbaum, F.R., Radiolabel d Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma.Hem. Onc. Clinics of N.A. 5(5):1013-1025 (1991).
Armitage, J.O. et al., Predicting therapeutics outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP),Cancer 50:1695 (1982).
Bhan, A.K., et al., Stages of B cell differentiation in human lymphoid tissue, J. Exp. Med., 154:737-749 (1981).
Boulianne, G.L. et al., Production of functional chimaeric mouse/human antibody,Nature 312:643 (Dec. 1984).
Brunner, K.T. et al., Quantitative assay of the lytic action of immune lymphoid cells on51Cr-labeled allogeneic target cells in vitro; inhibition by isoantibody and drugs,Immunology 14:181-189 (1968).
Buchsbaum, D.J., et al., A comparison of131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts, Int. J. Radiation Oncology Biol. Phys., 18:1033-1041 (1990).
Buchsbaum, D.J., et al., Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies, Cancer Research (Suppl.) 50:993s-999s (1990).
Buchsbaum, D.J., et al., Comparison of131I-and90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts, Int. J. Radiation Oncology Biol. Phys. 25:629-638 (1993).
Calvert, J.E., et al., Cellular events in the differentiation of antibody-secreting cells, Seminars in Hematology, 21(4):226-243 (1984).
Chomczynski, P. et al., Single step method of RNA isolation by acid guanidinlum thiocyanate-phenol-chloroform extraction,Anal. Biochem. 162:156-159 (1987).
Clark, E.A., et al., Role of the Bp35 cell surface polypeptide in human B-cell activation, Proc. Natl. Acad. Sci. USA, 82:1766-1770 (1985).
Cope, Antibody shows promise in treating B-cell lymphoma, Oncology, 8(4):100 (1994).
DeNardo, S.J., et al., Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody, Antibody, Immunoconjugates, and Radiopharmaceuticals, 1(1):17-33 (1988).
DeNardo, S.J., et al., The biologic window for chimeric L6 radioimmunotherapy, Cancer 73(3):1023-32 (1994).
Dickson, Scientists produce chimeric monoclonal abs,Genetic Engineering News 5/3(Mar. 1985).
Eary, J.F. et al. Imaging and Treatment of B-Cell Lymphoma,J. Nuc. Med. 31/8:1257-1268 (1990).
Einfeld, D.A. et al., Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains,EMBO 7:711 (1988).
Golay, J.T., et al., The CD20 (Bp35) antigen is involved in activation of B cells from the G0to the G1phase of the cell cycle, J. Immunology 135(6):3795-3801 (1985).
Goldenberg, D.M. et al., Targeting, dosimetry and radioimmunotherapy of B-Cell lymphomas with iodine-131-labeled LL2 monoclonal antibody,J. Clin. Onc. 9/4:548-564 (1991).
Greenberger, J.S., et al., Effects of monoclonal antibody and complement
Anderson Darrell R.
Hanna Nabil
Newman Roland A.
Rastetter William H.
Reff Mitchell E.
Biogen Idec Inc.
Schwadron Ronald B.
Sidley Austin LLP
LandOfFree
Anti-CD20 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CD20 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD20 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3992011